As of Mar 27
| +0.04 / +3.45%|
The 2 analysts offering 12-month price forecasts for Repros Therapeutics Inc have a median target of 5.25, with a high estimate of 5.50 and a low estimate of 5.00. The median estimate represents a +337.50% increase from the last price of 1.20.
The current consensus among 2 polled investment analysts is to Buy stock in Repros Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.